Navigation Links
Breast cancer cells recycle to escape death by hormonal therapy
Date:10/2/2008

Many breast cancer cells facing potentially lethal antiestrogen therapy recycle to survive, researchers say.

About 70 percent of breast cancer cells have receptors for the hormone estrogen, which acts as a nutrient and stimulates their growth. Patients typically get an antiestrogen such as tamoxifen for five years to try to starve them to death, says Dr. Patricia V. Schoenlein, cancer researcher in the Medical College of Georgia Schools of Medicine and Graduate Studies.

"About 50 to 60 percent of these women really benefit from hormonal therapy," says Dr. Schoenlein. Why others don't has been asked for at least two decades.

One reason may be breast cancer cells switch into a survival mode that normal cells also use when faced with starvation, according to research published in the September issue of Molecular Cancer Therapeutics. Dr. Schoenlein also is reporting on the research during the 2nd World Conference on Magic Bullets (Ehrlich II) Oct. 3-5 in Nrenberg, Germany.

It's called macroautophagy autophagy means "self eating" and within a week, breast cancer cells can reorganize component parts, degrade non-essentials and live in this state until antiestrogen therapy is stopped or the cells mutate and resume proliferation in the presence of tamoxifen. "It's like taking your foot off of the gas pedal of your car," says Dr. Schoenlein, corresponding author on the study. "The cancer cell is in idle, unable to grow or replicate. But the cell is smart enough to use component parts generated by macroautophagy for the most necessary things required for survival." She notes that macroautophagy can't be maintained indefinitely; cells can actually self-digest. "This is a time-buying strategy."

Chemotherapeutic drugs are more direct killers but also kill healthy cells and can be tolerated by patients only for relatively short periods. Antiestrogen therapy is more specific, targeting breast cancer cells that express estrogen receptors.

In the laboratory, 20-25 percent of breast cancer cells died when Dr. Schoenlein and colleagues gave antiestrogen continuously over time similar to how patients get it. More typically, the cells expressed increasing levels of macroautophagy and survived. "They don't grow, but they survive the therapy. They will grow if you take away the therapy." Adding a macroautophagy inhibitor promoted robust cell death.

"We believe targeting the autophagosome function will significantly improve the efficacy of hormonal treatment for estrogen-positive breast cancer," says the researcher. She recently received a three-year, $1.1 million National Cancer Institute grant to pursue that strategy.

She'll now look for ways to block macroautophagy in an animal model, including using chloroquine, a drug used to treat malaria. "We know patients can take it with few side effects," she says. If it works in animals, the drug, in combination with an antiestrogen, could move relatively quickly into human testing.

During autophagy, the internal pH for the recycling center of the reorganized cell gets acidic and chloroquine increases pH. "If you add this particular inhibitor of the recycling center, you alter the pH and block its ability to do what it is supposed to do," says Dr. Schoenlein.

A University of Pennsylvania team led by Dr. Craig Thompson reported in 2007 in The Journal of Clinical Investigation that chloroquine increased death of suicide-resistant lymphoma cells being treated with chemotherapy. Dr. Schoenlein will give chloroquine along with an antiestrogen and measure cell death.

"Most cancers probably use autophagy as a survival mechanism. You can either block the autophagosome with your therapy or you can make the cell eat itself to the point of no return and the cell self-destructs. You have to push it either way," she says. Although there are no known compounds in clinical use to induce self-destruction by autophagy, there is some evidence arsenic trioxide, a compound used in China to treat some aggressive cancers, prompts cancer cells to die from self digestion, she says. That and other compounds will no doubt be studied further, she says.

Dr. Schoenlein believes breast cancer survival during macroautophagy requires high activity of the tumor suppressor protein Rb and low levels of the lipid ceramide. Ceramide is vital but causes cell death at high levels. MCG researcher Erhard Bieberich and colleague Dr. Brian G. Condie at the University of Georgia showed in 2003 that high levels of ceramide kill cells that are unnecessary to the developing brain. The new studies will further explore the roles of Rb and ceramide in breast cancer survival during macroautophagy and determine if chloroquine can change their balance.


'/>"/>

Contact: Toni Baker
tbaker@mcg.edu
706-721-4421
Medical College of Georgia
Source:Eurekalert  

Related biology news :

1. The dietary supplement genistein can undermine breast cancer treatment
2. Breast cancer treatment resistance linked to signaling pathway
3. Expanding cell girth indicates seriousness of breast cancer
4. Stem cells may solve mystery of early pregnancy breast cancer protection
5. Vaccine against HER2-positive breast cancer offers complete protection in lab
6. 31st Annual San Antonio Breast Cancer Symposium
7. Growth factor predicts poor outcome in breast cancer
8. CSHL scientists identify new drug target against virulent type of breast cancer
9. Codeine not safe for all breastfeeding moms and their babies
10. New breastfeeding study shows most moms quit early
11. Foods high in conjugated linoleic acids can enrich breast milk
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Breast cancer cells recycle to escape death by hormonal therapy
(Date:1/6/2017)... 2017  SomaLogic announced today that it has ... by iCarbonX, the China -based ... Digital Health Ecosystem that can define each person,s ... biological, behavioral and psychological data, the Internet and ... SomaLogic will provide proteomics data and applications expertise ...
(Date:12/22/2016)... 20, 2016  As part of its longstanding mission to ... genetics company, recently released its latest children,s book, titled ... focuses on the topics of inheritance and variation of traits ... taught in elementary school classrooms in the US. ... illustrator Ariana Killoran , whose previous book with 23andMe, ...
(Date:12/16/2016)... , Dec. 16, 2016   IdentyTechSolutions America ... management products and solutions and a cutting-edge manufacturer ... that it is offering seamless, integrated solutions that ... entrance products. The solutions provide IdentyTech,s customers with ... their facilities from crime and theft. ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... 2017 BD (Becton, Dickinson and Company) (NYSE: ... will host a live webcast of its Annual Meeting of Shareholders ... The webcast can be accessed from the BD corporate website ... January 31, 2017. ... About BD BD is a global medical technology company ...
(Date:1/18/2017)... --  Parent Project Muscular Dystrophy (PPMD) , a nonprofit ... dystrophy (Duchenne) , today announced a $600,000 grant to ... (NJIT) and Talem Technologies (Talem) as part of the ... assist people living with Duchenne. PPMD is funding a ... computer, software, a force sensor and a motor – ...
(Date:1/18/2017)... Gainesville, FL (PRWEB) , ... January 18, 2017 ... ... muscle weakness and paralysis, today announced that it has submitted a 510(k) to ... stationary bikes that utilize MYOLYN’s patent-pending functional electrical stimulation (FES) technology. , ...
(Date:1/18/2017)... ... January 18, 2017 , ... Thirty-six startup companies in University ... the Pennsylvania Department of Community and Economic Development in 2016 as part of the ... the University City Keystone Innovation Zone and represent the highest number of awards to ...
Breaking Biology Technology: